Targeted drug delivery is one of the greatest challenges in nanomedicine. Extracellular vesicles (EVs) are promising natural carriers for therapeutic molecules, but making sure that they reach the right cells remains a key hurdle. A new publication by researchers from the Ludwig Boltzmann Institute for Traumatology and the University of Applied Sciences Upper Austria presents a versatile technology that could help overcome this challenge.
The study introduces a rapid and flexible method for decorating the surface of extracellular vesicles with targeting molecules. Rather than redesigning EVs for every new application, the platform allows researchers to equip them with different ligands depending on the desired target. This makes the technology adaptable to a wide range of biomedical applications and simplifies the development of targeted EV-based therapies.
To demonstrate the platform’s versatility, the researchers successfully directed extracellular vesicles towards HER2-positive cancer cells and CCR2-positive immune cells. The technology provides a flexible foundation for developing future EV-based therapies that can selectively interact with specific cells and tissues.
The study was carried out jointly by researchers from the Ludwig Boltzmann Institute for Traumatology and the University of Applied Sciences Upper Austria. The publication reflects the collaborative research approach that is at the heart of the NanoPrecMed Consortium, where partners contribute their expertise to develop new technologies for effective precision nanomedicine.